Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences POC Diagnostics, Global Health-Viral Diseases 2017

John T McDevitt's Biography



John T McDevitt, Chair, Department of Biomaterials, New York University College of Dentistry Bioengineering Institute

John T. McDevitt serves as the Chair for the Department Biomaterials and Biomimetics at New York University College of Dentistry and is a pioneer in the development of ‘programmable bio-nano-chip’ technologies. He has a strong track record of translating essential bioscience discoveries into real-world clinical practice. In this capacity he serves as the Scientific Founder for several companies in areas related to medical microdevice technologies. His most recent company, SensoDx, features a universal platform sensor technology with capacity to digitize biological signatures for a broad range of key health conditions. McDevitt and his team over the past decade have raised over $25M in Federal and Foundation support. His recent research has been sponsored by major programs funded by the National Institute of Dental and Craniofacial Research (NIDCR) division of the National Institutes of Health (NIH), the Bill and Melinda Gates Foundation, Cancer Prevention Research Institute of Texas (CPRIT), the National Aeronautics and Space Administration (NASA) and the United Kingdom’s Home Office Scientific Development Branch.

McDevitt and his team have written more than 185 peer-reviewed scientific manuscripts and have contributed to more than 100 patents and patent applications. This work was recognized with the “Best of What's New Award” in the Medical Device Category for 2008 by Popular Science as well as for the “Best Scientific Advances Award” in 1998 by the Science Coalition. Dr. McDevitt’s individual honors include the Presidential Young Investigator Award, the 2010 California Polytechnic Distinguished Alumni Award and the Exxon Education Award. Over the past 5 years Dr. McDevitt has served as the Principal Investigator for 6 major clinical trials and 2 clinical pilot studies, all involving the programmable bio-nano-chip. Through these clinical efforts, mini-sensor ensembles are being developed for major diseases in the areas of oral cancer, cardiac heart disease, trauma, drugs of abuse, ovarian cancer and prostate cancer.

John T McDevitt Image

Programmable Bio-Nano-Chip Platform: A Point-of-Care Biosensor System with the Capacity to Learn

Tuesday, 3 October 2017 at 10:00

Add to Calendar ▼2017-10-03 10:00:002017-10-03 11:00:00Europe/LondonProgrammable Bio-Nano-Chip Platform: A Point-of-Care Biosensor System with the Capacity to LearnPOC Diagnostics, Global Health-Viral Diseases 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

The combination of point-of-care (POC) medical microdevices and machine learning has the potential transform the practice of medicine. In this area, scalable lab-on-a-chip (LOC) devices have many advantages over standard laboratory methods, including faster analysis, reduced cost, lower power consumption, and higher levels of integration and automation. Despite significant advances in LOC technologies over the years, several remaining obstacles are preventing clinical implementation and market penetration of these novel medical microdevices. Similarly, while machine learning has seen explosive growth in recent years and promises to shift the practice of medicine toward data-intensive and evidence-based decision making, its uptake has been hindered due to the lack of integration between clinical measurements and disease determinations. In this talk, recent developments in the programmable bio-nano-chip (p-BNC) system, a biosensor platform with the capacity for learning will be highlighted. The p-BNC is a ‘platform to digitize biology’ in which small quantities of patient sample generate immunofluorescent signal on agarose bead sensors that is optically extracted and converted to antigen concentrations. The platform comprises disposable microfluidic cartridges, a portable analyzer, automated data analysis software, and intuitive mobile health interfaces. The single-use cartridges are fully integrated, self-contained microfluidic devices containing aqueous buffers conveniently embedded for POC use. A novel fluid delivery method was developed to provide accurate and repeatable flow rates via actuation of the cartridge’s blister packs. A portable analyzer instrument was designed to integrate fluid delivery, optical detection, image analysis, and user interface, representing a universal system for acquiring, processing, and managing clinical data while overcoming many of the challenges facing the widespread clinical adoption of LOC technologies. We demonstrate here the p-BNC’s flexibility through the completion of multiplex assays within the single-use disposable cartridges for numerous clinical applications including prostate cancer, ovarian cancer, and acute myocardial infarction. Toward the goal of creating ‘sensors that learn’, we have developed and describe here the Cardiac ScoreCard, a clinical decision support system for a spectrum of cardiovascular disease. The Cardiac ScoreCard approach comprises a comprehensive biomarker panel and risk factor information in a predictive model capable of assessing early risk and late-stage disease progression for heart attack and heart failure patients.


Add to Calendar ▼2017-10-02 00:00:002017-10-04 00:00:00Europe/LondonPOC Diagnostics, Global Health-Viral Diseases 2017POC Diagnostics, Global Health-Viral Diseases 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com